ReviewBioengineering (Basel, Switzerland)2021
COVID-19 Diagnostic Strategies. Part I: Nucleic Acid-Based Technologies.
Review in Bioengineering (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Investigation of DNA Hybridization on Nano-Structured Plasmonic Surfaces for Identifying Nasopharyngeal Viruses.Bioengineering (Basel, Switzerland) · 2023Article
- A microfluidic biosensor architecture for the rapid detection of COVID-19.Analytica chimica acta · 2023Article
- Emerging Field-Effect Transistor Biosensors for Life Science Applications.Bioengineering (Basel, Switzerland) · 2023Article
- A Retrospective Population Study of 385 191 Positive Real-Time Reverse Transcription-Polymerase Chain Reaction Tests For SARS-CoV-2 from a Single Laboratory in Katowice, Poland from April 2020 to July 2022.Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- COVID-19 diagnostic approaches with an extensive focus on computed tomography in accurate diagnosis, prognosis, staging, and follow-up.Polish journal of radiology · 2023Review
- Deep Learning for Detecting COVID-19 Using Medical Images.Bioengineering (Basel, Switzerland) · 2022Article
- CRISPR-based systems for sensitive and rapid on-site COVID-19 diagnostics.Trends in biotechnology · 2022Review
- Review
- Review
- A Study of the Detection of SARS-CoV-2 ORF1ab Gene by the Use of Electrochemiluminescent Biosensor Based on Dual-Probe Hybridization.Sensors (Basel, Switzerland) · 2022Article
- Microfluidics-Based Biosensing Platforms: Emerging Frontiers in Point-of-Care Testing SARS-CoV-2 and Seroprevalence.Biosensors · 2022Review
- Evaluation of the QIAstat-Dx RP2.0 and the BioFire FilmArray RP2.1 for the Rapid Detection of Respiratory Pathogens Including SARS-CoV-2.Frontiers in microbiology · 2022Article
- Recent findings and applications of biomedical engineering for COVID-19 diagnosis: a critical review.Bioengineered · 2021Review
- A Portable Device for LAMP Based Detection of SARS-CoV-2.Micromachines · 2021Article
- Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Pathology, research and practice · 2021Review
- Towards Fully Integrated Portable Sensing Devices for COVID-19 and Future Global Hazards: Recent Advances, Challenges, and Prospects.Micromachines · 2021Review
- Genomic chronicle of SARS-CoV-2: a mutational analysis with over 1 million genome sequences.Turkish journal of biology = Turk biyoloji dergisi · 2021Article
- A comprehensive review on current COVID-19 detection methods: From lab care to point of care diagnosis.Sensors international · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused respiratory infection, resulting in more than two million deaths globally and hospitalizing thousands of people by March 2021. A considerable percentage of the SARS-CoV-2 positive patients are asymptomatic or pre-symptomatic carriers, facilitating the viral spread in the community by their social activities. Hence, it is critical to have access to commercialized diagnostic tests to detect the infection in the earliest stages, monitor the disease, and follow up the patients. Various technologies have been proposed to develop more promising assays and move toward the mass production of fast, reliable, cost-effective, and portable PoC diagnostic tests for COVID-19 detection. Not only COVID-19 but also many other pathogens will be able to spread and attach to human bodies in the future. These technologies enable the fast identification of high-risk individuals during future hazards to support the public in such outbreaks. This paper provides a comprehensive review of current technologies, the progress in the development of molecular diagnostic tests, and the potential strategies to facilitate innovative developments in unprecedented pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.